Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antifibrinolytic agent |
| gptkbp:ATCCode |
B02AA02
|
| gptkbp:bioavailability |
30-50% (oral)
|
| gptkbp:brand |
Cyklokapron
Lysteda |
| gptkbp:CASNumber |
1197-18-8
|
| gptkbp:chemicalClass |
lysine analog
|
| gptkbp:contraindication |
subarachnoid hemorrhage
active intravascular clotting history of thromboembolic disease |
| gptkbp:discoveredBy |
Shosuke Okamoto
|
| gptkbp:discoveredIn |
1962
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C8H15NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
tranexamic acid
|
| gptkbp:interactsWith |
oral contraceptives
factor IX complex concentrates tissue plasminogen activators |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits activation of plasminogen to plasmin
|
| gptkbp:meltingPoint |
300°C
|
| gptkbp:metabolism |
minimal
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
5526
|
| gptkbp:riskFactor |
increased risk of thrombosis
|
| gptkbp:routeOfAdministration |
oral
topical intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea visual disturbances allergic skin reactions |
| gptkbp:solubility |
water soluble
|
| gptkbp:synonym |
trans-4-(aminomethyl)cyclohexanecarboxylic acid
|
| gptkbp:UNII |
O5L944J8E4
|
| gptkbp:usedFor |
treatment of heavy menstrual bleeding
treatment of hereditary angioedema prevention of excessive bleeding during surgery treatment of trauma-related bleeding |
| gptkbp:usedIn |
hemophilia
orthopedic surgery trauma care dental surgery cardiac surgery gynecological surgery epistaxis (nosebleeds) melasma (topical) |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:hereditary_hemorrhagic_telangiectasia
|
| gptkbp:bfsLayer |
6
|